Rosetta Genomics Gets Extension from Nasdaq to Regain Compliance
February 08, 2011
Rosetta Genomics Gets Extension from Nasdaq to Regain Compliance
Rosetta received an extension to come into compliance with one regulation, but it was notified this week that it is now not in compliance with the $1 per share closing price requirement.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Rosetta Genomics Warned by Nasdaq on Second Listing Compliance Issue
April 23, 2012 / GenomeWeb Daily News - Rosetta Pays Prometheus $650K; Not in Compliance With Nasdaq Requirement
December 2, 2011 / GenomeWeb Daily News - Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News - Sanra Labs Makes Full Payment to Rosetta Genomics, Settling Dispute
May 10, 2013 / GenomeWeb Daily News - Rosetta Releases miRview Kidney Test Validation Study, Anticipates Medicare Coverage Decision
April 4, 2013 / Gene Silencing News